Dr. Martin on the Frontline Treatment Landscape of MCL

Video

Peter Martin, MD, discusses the frontline treatment landscape of mantle cell lymphoma.

Peter Martin, MD, chief, the Lymphoma Program, Meyer Cancer Center, associate professor of medicine, Weill Cornell Medicine, discusses the frontline treatment landscape of mantle cell lymphoma (MCL).

Unlike other lymphoma subtypes, there is not an established first-line standard of care in MCL, says Martin. Instead, there is a series of available options to select from.

Generally, younger, fitter patients are given intensive therapy, whereas older patients or those with multiple comorbidities are likely to receive less intensive chemoimmunotherapy regimens, explains Martin. 

The ultimate goal of therapy is to minimize the burden of the disease and maximize the patient’s quality of life, concludes Martin. 

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD